IgGdriven

IgGdriven is a descriptive term used in immunology to refer to immune responses, diseases, or therapies in which Immunoglobulin G (IgG) antibodies are the dominant mediator. It is not a formal diagnosis and is used to contrast IgG-mediated processes with those driven by other antibody classes (IgM, IgA) or by cellular immunity.

Mechanisms: IgG mediates neutralization, opsonization for phagocytosis, and antibody-dependent cellular cytotoxicity (ADCC) via Fc gamma receptors on NK cells, macrophages, and neutrophils. It can activate the classical complement pathway through C1q binding and form immune complexes that influence antigen presentation and inflammation. IgG subclass distribution (for example, IgG1 and IgG3 versus IgG2 and IgG4) shapes the strength and quality of these effector functions.

Context and examples: In vaccines and infections, a strong IgG-driven response is often associated with long-lasting protection. In autoimmune disease, pathogenic IgG autoantibodies can drive tissue injury by activating Fc receptors and complement. Therapeutic approaches may aim to enhance beneficial IgG responses (as with monoclonal antibodies) or reduce harmful IgG activity (for example, plasmapheresis, IVIG, or Fc receptor blockade).

Assessment and usage: Researchers evaluate IgG titers, subclass proportions, avidity, and functional assays to quantify the IgG-driven component of immunity. The term remains a descriptive label used in specific contexts rather than a standardized clinical category.